Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Neutral +5

Here is Why Zoetis (ZTS) is One of the Best NYSE Stocks According Analysts

AI-generated analysis

πŸ“ˆ Zoetis (ZTS) reported Q1 2026 revenue of $2.3 billion, representing a 3% increase on a reported basis but flat organic growth.

πŸ’° Net income reached $601 million with adjusted diluted EPS growing 9% to $1.53.

⚠️ CEO Kristin Peck highlighted a challenging environment due to increased price sensitivity and intensified competition in dermatology and parasiticides.

πŸ“‰ The US segment saw an 8% revenue decline to $1.1 billion driven by lower companion animal product sales and generic competition.

🌍 In contrast, the International segment grew 17% to $1.1 billion, boosted by livestock demand and fiscal reporting alignments.

πŸ„ Livestock sales remained a strong global performance area with a 7% organic increase in the US and 14% internationally.

πŸ“ Zoetis revised its full-year 2026 revenue guidance to between $9.68 and $9.96 billion, indicating 2% to 5% organic growth.

πŸ’Š The company maintains a pipeline of over 12 potential blockbusters in development.

πŸ’Ό Zoetis has a pending acquisition of Neogen’s animal genomics business expected to close in H2 2026.

🌐 Zoetis operates globally as an animal health company specializing in vaccines, medicines, biodevices, and precision animal health products.

πŸ” Analysts classify ZTS as one of the best NYSE stocks to buy despite some regional headwinds.

βš–οΈ The article notes that AI stocks may offer greater upside potential and less downside risk compared to ZTS.

πŸ“… This financial report was released on May 7, covering Q1 2026 performance metrics.

Bullish Signals
  • Zoetis Inc. (NYSE:ZTS) reported Q1 2026 revenue of $2.3 billion with adjusted diluted EPS growing 9% to $1.53, despite organic revenue being flat.
  • The International segment demonstrated strong momentum with a 17% revenue growth to $1.1 billion, driven by robust demand in livestock and parasiticides.
  • Livestock sales served as a significant bright spot globally, posting a 7% organic increase in the US and a 14% increase internationally.
  • The company's pipeline includes over 12 potential blockbuster drugs, indicating substantial future growth prospects.
  • Zoetis has a pending acquisition of Neogen's animal genomics business expected to close in H2 2026, which is expected to strengthen its genomic capabilities.
  • Despite challenging conditions, the company revised its full-year 2026 revenue guidance to between $9.68 and $9.96 billion, projecting organic growth of 2% to 5%.
Risk Factors
  • The article suggests Zoetis offers less upside potential compared to AI stocks, explicitly carrying higher downside risk according to analyst comparisons.
  • Q1 2026 revenue growth was flat on an organic basis despite a reported increase, indicating underlying sales weakness masked by accounting adjustments.
  • Net income reached $601 million with adjusted diluted EPS growing 9% to $1.53, but this growth was noted against a challenging operating environment characterized by increased price sensitivity among pet owners.
  • Intensified competition in dermatology and parasiticides segments has led to softer demand for premium products, potentially impacting future margins.
  • The US segment experienced an 8% revenue decline to $1.1 billion, driven by lower companion animal product sales and generic competition pressures.
  • Zoetis revised its full-year 2026 revenue guidance downward to between $9.68 and $9.96 billion, with organic growth expectations constrained to a narrow range of 2% to 5%.
Full Analysis
Zoetis Inc. (NYSE:ZTS) reported first quarter 2026 financial results on May 7, with revenue of $2.3 billion reflecting a 3% reported increase but flat organic growth. Net income was $601 million and adjusted diluted EPS rose 9% to $1.53. CEO Kristin Peck highlighted a challenging environment driven by price sensitivity among pet owners and heightened competition in dermatology and parasiticides, which dampened demand for premium products. Regional performance diverged sharply; the US segment saw an 8% revenue decline to $1.1 billion due to lower companion animal sales and generic competition, while the International segment surged 17% to $1.1 billion. The international growth was fueled by strong livestock demand in parasiticides, a $100 million benefit from fiscal year reporting alignments, organic livestock sales rising 7% in the US and 14% globally. Guidance for full-year 2026 revenue has been revised to between $9.68 billion and $9.96 billion, with organic growth expectations set at 2% to 5%. The company maintains a pipeline of over 12 potential blockbuster products and is pursuing the acquisition of Neogen’s animal genomics business, expected to close in the second half of 2026. Despite these fundamentals, the article notes that certain AI stocks are considered by analysts to offer greater upside with less downside risk. The text references a report on undervalued AI stocks benefiting from potential Trump-era tariffs and onshoring trends as an alternative investment consideration.